How to Help Your Patients Save Money on Ibalizumab: A Provider's Guide to Savings Programs

Why Ibalizumab Cost Is a Clinical Issue, Not Just a Financial One

For HIV providers, cost barriers to ibalizumab (Trogarzo) are a patient safety issue. Ibalizumab is often one of the last effective antiretroviral options for heavily treatment-experienced (HTE) patients with multidrug-resistant (MDR) HIV-1. Without consistent access—every 14 days, without interruption—patients risk viral rebound, further resistance development, and clinical deterioration.

At an estimated list price of approximately $9,000 or more per month, ibalizumab is unaffordable without insurance coverage or financial assistance. Understanding the full landscape of available savings programs—and proactively connecting patients to them—is an essential part of ibalizumab prescribing.

Program 1: Thera Patient Support Co-Pay Assistance (Commercial Insurance)

For commercially insured patients, the Thera Patient Support co-pay assistance program is the most impactful tool available. Eligible patients may pay as little as $0 per injection.

Provider Action Steps:

Do not wait for the patient to call—have your care coordinator contact Thera Patient Support directly when you initiate ibalizumab: 1-833-238-4372

Thera Patient Support will conduct a benefits investigation, initiate prior authorization, and enroll eligible patients in co-pay assistance simultaneously

Note: co-pay assistance is not available for patients covered by Medicare, Medicaid, or other federal/state programs

Program 2: AIDS Drug Assistance Programs (ADAP) — For Uninsured/Underinsured Patients

ADAP is the critical safety net for patients who are uninsured or underinsured. Funded through the Ryan White HIV/AIDS Program and administered by states, ADAPs provide HIV medications including ibalizumab at no cost to eligible recipients.

Key clinical considerations:

ADAP formularies vary by state—confirm ibalizumab is covered in your state before assuming eligibility

Enrollment can take time—begin the ADAP process as early as possible, parallel to other access steps

Thera Patient Support can assist with ADAP eligibility determination and enrollment paperwork

Some ADAPs also pay Medicare Part B premiums and co-insurance for dual-eligible patients

Program 3: Patient Assistance Program (PAP) — Direct Manufacturer Assistance

Theratechnologies offers a Patient Assistance Program for patients who do not have insurance coverage and do not qualify for ADAP. Eligibility is income-based. For patients who fall through other coverage gaps, the PAP may provide ibalizumab at no cost.

Provider Action Step: Have your care team contact Thera Patient Support (1-833-238-4372) to assess PAP eligibility alongside other assistance options.

Program 4: Medicare Part B — Optimizing Coverage for Infusion Drugs

Ibalizumab is billed under Medicare Part B as a provider-administered infusion drug (HCPCS J1746). Standard Part B cost sharing is 20% after the annual deductible, with no cap on out-of-pocket expenses—which can be substantial given ibalizumab's cost.

Strategies to reduce Medicare patient out-of-pocket costs:

Medicare Supplement (Medigap): Medigap plans F, G, and N cover Part B coinsurance. Advise Medicare-eligible patients to review Medigap options during Open Enrollment.

Qualified Medicare Beneficiary (QMB): Medicaid's QMB program pays Medicare Part A and B premiums, deductibles, and coinsurance for eligible low-income beneficiaries. This can eliminate Part B out-of-pocket costs entirely.

State ADAP Medicare cost-sharing assistance: Many state ADAPs assist HIV-positive Medicare beneficiaries by paying Part B premiums and co-insurance—check your state's ADAP formulary.

Clinical Workflow: Integrating Financial Navigation Into Ibalizumab Prescribing

A structured workflow ensures no patient falls through the financial cracks:

At prescribing decision: Alert care coordinator to begin Thera Patient Support engagement same day.

Benefits investigation (Day 1–3): Thera Patient Support confirms insurance coverage, PA requirements, and co-pay assistance eligibility.

PA submission (Day 3–5): Submit PA with complete clinical documentation. Thera Patient Support can assist.

If PA pending/denied: Engage appeal process + evaluate ADAP/PAP as bridge coverage.

At 6 months: Begin PA renewal process 4–6 weeks before expiration. Reassess patient financial assistance status.

How medfinder Supports Your Practice

Beyond financial assistance, access logistics—finding an infusion site, confirming specialty pharmacy availability—add administrative burden to HIV practices. medfinder calls pharmacies and infusion providers near a patient's location to identify which ones can fill the prescription—reducing phone time for your care coordinators and getting patients to treatment faster. Learn more at medfinder.com/providers.

For a companion guide on navigating ibalizumab access and prior authorization, see: Ibalizumab Access Challenges: What Providers and Prescribers Need to Know in 2026.